VolitionRx Announces Pricing of $4.6 Million Public Offering

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Phreesia, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class...

He Predicted Gold at $5,000. Now He Says This $2 Stock Could Be Even Bigger.

MEDP DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Medpace Holdings, Inc. Investors to Secure Counsel Before Important June...

Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications

Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE...

FCM marks 125 years as municipal leaders gather in Edmonton

Diasome Presents Phase 2b Data Demonstrating HDV™-Insulin Lispro Maintains Glycemic Control While Reducing Hypoglycemia in Adults with Type...

Monday, June 8, 2026

Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

GoHealth, Inc. to strengthen its position ahead of AEP 2026 through Restructuring Process supported by key stakeholders

Photo Scanning Services 2026 - iMemories Launched Photo Scanning Services for Families Across the USA

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than...

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss...

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial in people living with obesity showed targeted 34% visceral and...

Butler County Jury Returns $12.5 Million Verdict Against Chesterwood Village, Including Punitive Damages, in Wrongful Death of 83-Year-Old...

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a...

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Veritone, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action ...